1. BMS is a composite of several bare metal stents as a representation of the BMS category.
2. An odds ratio is a method of comparing the odds of an event between two groups.
3. A rate ratio was calculated instead of an odds ratio.
4. Median follow-up was 1.9 years in this study.
5. Median follow-up was 2.2 years in this study.
6. Palmerini T, et al. The Lancet. March 23, 2012; 379:1393-1402.
7. Bangalore S, et al. Circulation May 14, 2012;125:2873-2891.
8. Bangalore S, et al. British Medical Journal, Aug 10, 2012. 345:e5170 doi: 10.1136/bmj.e5170.
9. Palmerini T, et al. JACC. June 7, 2013;62:496-504.
10. Bangalore S, et al. Circ Cardiovasc Interv, Aug 6, 2013. doi: 10.1161/ circinterventions. 113.000415.
Valgimigli, M, Effects of Cobalt-chromium everolimus eluting or bare metal stent on fatal and non-fatal cardiovascular events. A patient-level meta analysis. EuroPCR 2014.
*BMS is a composite of several bare metal stents as a representation of the BMS category
1. Bangalore S, et al. BMJ, Nov 2013. 347:f6625 doi: 10.1136/bmj.f6625.
2. Palmerini T et al. JACC Nov 2013 doi: 10.1016/j.jacc.2013.09.061.
3. An odds ratio is a method of comparing the incidence of events between two groups.
4. A rate ratio was calculated instead of an odds ratio.
"Meta-analyses should be regarded as hypothesis-generating and the findings of Palmerini and colleagues suggest that a randomized trial of CoCr EES and BMS is desirable." Ormiston, The Lancet, April 2012
The XIENCE system’s clinical outcomes result from its components, including: a thin-strut, flexible ring and link design, with favorable strut apposition, no metal-to-metal touch points, and low strain upon expansion; the novel Everolimus compound; and the multi-layer coating and primer technologies, using a fluorinated polymer class known for cardiovascular implants, and known for having excellent mechanical properties.
Note: The above charts are illustrative representation of various odds ratios from the sourced meta-analyses.
Note: XIENCE has demonstrated reduced event rates in the safety endpoints of stent thrombosis, death and MI versus several BMS and BP-DES in multiple large scale meta-analyses. Sources: Dr. Valgimigli, EuroPCR 2014; Palmerini et al. Lancet. 2012;379:1393-402; Bangalore et al. Circulation 2012;125:2873-2891